USV Pvt. Ltd. has launched OnArni, a combination of Sacubitril and Valsartan, for treating heart failure, available at an affordable price of Rs. $8 is the cost for each tablet of 50mg. This affordable solution helps tackle the increasing...
India's drug pricing regulator has raised the maximum price of 11 scheduled formulations by 50% to guarantee their accessibility. The majority of these medications are commonly used as initial treatment options for a range of conditions such as...
In a bid to expand its reach into underserved markets, Indian diagnostics chain Metropolis Healthcare is enhancing its presence across North and East India by establishing 25 new laboratories and 500 centres in Tier III cities. “We have expanded o...
Arbele, a leading innovator in biopharmaceutical and biotechnology focused on targeting cadherin-17 (CDH17), has announced a strategic collaboration in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of...
The Indian pharmaceutical market (IPM) experienced a 5.3% growth in September this year, fueled by significant therapies demonstrating favorable value growth, reported by Pharmarack. Urology, cardiac, and dermatology treatments experienced close...
Zydus Lifesciences Ltd announced that it has been granted final approval by the FDA to produce paliperidone extended-release tablets in doses of 1.5 mg, 3 mg, 6 mg, and 9 mg. Paliperidone extended-release tablets are prescribed for treating...
Aerogen, a leading global company in acute-care aerosol drug delivery based in Ireland, partnered with the Indian Association of Respiratory Care (IARC) to advance respiratory therapy education and enhance patient care throughout India...
India's pharmaceutical and meditech sectors are projected to continue their growth momentum throughout the current fiscal year despite a global economic slowdown, A senior government official stated. Secretary Arunish Chawla announced on the...
.webp)
Bayer and MOMA Therapeutics, Inc., a biopharmaceutical company in the clinical stage that focuses on discovering and creating precise therapeutics, have declared a collaboration. This partnership involves an option and exclusive license agreement...
Zealand Pharma A/S, a biotech company specializing in peptide-based drugs, revealed that the FDA has issued a Complete Response Letter (CRL) for Part 1 of the NDA for dasiglucagon for treating hypoglycemia in children with CHI. The CRL is...
, CDSCO.jpg)
.jpg)